In our quest to understand why dimethyl sulfoxide (DMSO) can cause growth arrest and
terminal differentiation of transformed cells, we followed a path that led us to discover …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

Histone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer
agents. Several of these compounds are in clinical trials with significant activity against a …

Although targeted therapy is yielding promising results in the treatment of specific cancers,
drug resistance poses a problem. We develop a mathematical framework that can be used …

Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents.
Several HDAC inhibitors are in clinical trials and have shown significant activity against a …

Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal
signaling has been linked with tumor development and growth. Constitutive activated TKs …

Targeted cancer therapy with imatinib (Gleevec) has the capability to drive chronic myeloid
leukemia (CML) into clinical remission. Some patients, particularly those with advanced …

Histone deacetylases (HDACs) and histone acetyltransferases are enzymes that regulate
chromatin structure and function through the removal and addition, respectively, of the acetyl …

Cyclin-dependent kinases (CDKs) have long been known to be the main facilitators of the
cell proliferation cycle. However, they also play important roles in the regulation of the RNA …

Background Similar to tissue stem cells, primitive tumor cells in chronic myelogenous
leukemia have been observed to undergo quiescence; that is, the cells can temporarily stop …